Navigation Links
ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema
Date:3/4/2009

- Hereditary Angioedema (HAE) and the Dawn of New Therapeutics -

EXTON, Pa., March 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio webcast of its 'Teach-in' educational event for investors on Hereditary Angioedema (HAE), on Tuesday, March 10, 2009. Lectures will be provided by Anthony J. Castaldo and Janet Long, president and vice president, respectively, of the U.S. Hereditary Angioedema Association (HAEA), and Aleena Banerji, M.D., an HAE specialist at Massachusetts General Hospital.

The 'Teach-in', entitled 'Hereditary Angioedema (HAE) and The Dawn of New Therapeutics' will be held from 5:00 P.M. until 6:30 P.M. Eastern Time on Tuesday March 10, 2009.

"We are thrilled to enlist the participation of these key opinion leaders in the field of hereditary angioedema, who each day deal with the severe ramifications of HAE in their patients, families, and constituents," commented Will Roberts, ViroPharma's vice president of corporate communications. "As the proud stewards of the only approved C1 inhibitor therapy on the market, ViroPharma is committed to fostering our role as leaders in the space through the execution of essential disease awareness and investor programs."

A live audio webcast of the meeting may be accessed via the investor section of the ViroPharma corporate website, http://www.viropharma.com. The archive of the meeting will be available through March 24, 2009.

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients wit
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
2. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
3. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. ViroPharma Provides Update on Vancocin(R)
5. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
6. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
7. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
8. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
9. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (PRWEB) July 23, 2014 “Unlike most ... focus on developing your own unique gifts, talents and ... and clichéd sales verbiage, “says Ja Marr Brown. ... Sales Story?" which chronicles Brown’s transformation from nearly getting ... of The Year, winning every sales contest offered and ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The ... ratified today a robust trial for a defined ... of risk adjusting relevant quality measures for sociodemographic ... NQF policy.     , Sociodemographic factors can be socioeconomic, ... race, ethnicity, and primary language. Growing evidence ...
(Date:7/23/2014)... 23, 2014 In preparation for National ... Millennium Treatment Group is providing tips on choosing a ... society ever since man first figured out the process ... has existed since shortly thereafter. Its basis lies in ... then developing a way to combat that problem while ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, ... overweight American children and teens look in the mirror ... officials reported Wednesday. "Being overweight or obese is ... pressure, high cholesterol and diabetes," said lead researcher Neda ... Disease Control and Prevention,s National Center for Health Statistics. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Inventor and ... From football games to the gas pump – sharing ... on Wednesday, July 30 at Noon. , With 24 ... has more patents than anyone in the General Assembly ... superimposed yellow line yard marker as seen on television, ...
Breaking Medicine News(10 mins):Health News:Using Your Story and Not Technique to Achieve Sales Success 2Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Celebrating Innovation and Invention 2
... synthetic bone matrix offers hope for babies born with craniosynostosis, ... fuse too soon. Implants replacing some of the infant,s bone ... currently used to treat the condition. "The remarkable thing ... matrix changes what the cells around it do. Cells begin ...
... disease, stroke more likely for organ recipients with sleep ... News) -- Kidney transplant patients with sleep apnea are ... and stroke, Hungarian researchers say. , The study of ... moderate to severe sleep apnea, a rate similar to ...
... and costs, study finds , THURSDAY, Nov. 19 (HealthDay ... angiography is quicker, more accurate and much less expensive ... to moderate enzyme and EKG scores, according to a ... pain patients at 16 emergency rooms who were randomly ...
... 19 2009 has been a monumental year for ... from QUITPLAN Services, QuitCash Challenge, helped the 31-year-old Columbia ... The Challenge. Nearly 2,000 Minnesotans, including Doug, attempted to ... win the $5,000 grand prize. , On Thursday, November ...
... Official Statement by Teamsters General President Jim Hoffa ... Jim Hoffa issued the following statement today about the Senate ... health plans that will mean a huge middle-class tax hike ... would impose an excise tax on insurers for higher-cost health ...
... Nov. 19 Monogram Energy, Inc. ("Monogram") (Pink Sheets: ... of Triad Therapeutics, Inc. ("Triad"), which was effective as ... the Stock Purchase and Recapitalization Agreement, shareholders of Monogram ... exchange for approximately 95% ownership to the Triad shareholders ...
Cached Medicine News:Health News:Bone implant offers hope for skull deformities 2Health News:Kidney Transplant, Sleep Disorder May Add Up to Trouble 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 3Health News:Monogram Energy, Inc. Acquires Triad Therapeutics, Inc. 2
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
... 16, 2012 /PRNewswire-iReach/ -- Chronic pain is ... causes of persistent, debilitating back pain. Chicago resident Pedro ... livelihood and soured his outlook on life. After taking ... he finally found relief with non-surgical treatment at the ...
...  Rubicon Genomics, Inc., a leader in the development ... the performance and capabilities of DNA and RNA ... announced the launch of the first product in ... designed and optimized for next generation sequencing (NGS).  ...
Cached Medicine Technology:The Illinois Back Institute Helps Patient Beat Debilitating Back Pain 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 3
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: